Takeda Pharmaceutical (TAK) Current Assets (2017 - 2026)

Takeda Pharmaceutical's Current Assets history runs 10 years deep, the most recent figure standing at $19.7 billion for Q1 2026.

• On a quarterly basis, Current Assets rose 19.25% year-over-year to $19.7 billion in Q1 2026; TTM through Mar 2026 was $19.7 billion, a 19.25% increase from a year earlier, with the FY2026 full-year figure at $20.5 billion, up 24.04% from the prior year.
• Current Assets advanced to $19.7 billion in Q1 2026 per TAK's latest filing, from $88.4 million in the prior quarter.
• Across five years, Current Assets topped out at $19.7 billion in Q2 2022 and bottomed at $24.1 million in Q2 2024.
• The 5-year median for Current Assets is $111.1 million (2023), against an average of $4.7 billion.
• Across the five-year window, Current Assets sank 99.46% in 2023 and surged 71826.69% in 2025, its largest moves.
• Year by year, Current Assets stood at $52.1 million in 2022, then surged by 150.93% to $130.7 million in 2023, then soared by 236.25% to $439.3 million in 2024, then sank by 79.88% to $88.4 million in 2025, then soared by 22196.62% to $19.7 billion in 2026.
• Per Business Quant, the three latest TAK Current Assets figures stand at $19.7 billion (Q1 2026), $88.4 million (Q4 2025), and $87.1 million (Q3 2025).